NASDAQ: ADMA CLASS ACTION NOTICE: Berger Montague Encourages ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Inquire About a Securities Fraud Class Action

Berger Montague announced a securities class action against ADMA Biologics for alleged “channel stuffing” that purportedly inflated 2025 revenue growth. Culper Research estimated that without the alleged distributor stockpiling via rebates/extended terms, ADMA would have seen a 3% revenue decline versus the reported 20% growth. The stock fell $2.26 (-16%) on March 24, 2026 (to $11.33) and then another $1.70 (-15%) on March 25 (to $9.63), reflecting a material negative repricing.

Analysis

This is less a headline event than a credibility reset. If the distributor inventory and rebate allegations are directionally right, the market is still underpricing the second-order effect: a forward revenue air pocket plus margin compression as the company has to normalize terms, which can turn a perceived growth story into a working-capital story overnight. That matters more than the lawsuit itself because small-cap biotech multiples are usually pinned to durability of growth and cash conversion; once those are questioned, valuation can re-rate quickly and financing flexibility can tighten.

The near-term risk is that headline-driven selling may already have front-loaded some of the damage, so chasing the move after a two-day air-pocket is not ideal unless new evidence arrives. The real catalysts are the next quarterly filing, inventory/receivables trends, and any SEC or auditor scrutiny over the next 1-3 months; those are what would validate or falsify the thesis. Watch for a stabilization in days inventory outstanding and gross margin, because if reported growth was pulled forward, those metrics should deteriorate as channel inventory clears; if they do not, the bear case loses force. Relative winners are cleaner IVIG / plasma names such as GRFS, CSL, and TAK over a 6-18 month horizon, because capital will likely rotate toward businesses with more believable organic growth and less legal overhang.

Key Decisions for Investors

• Do not chase a fresh outright short immediately after the drawdown; wait for a 1-3 month confirmation point in the next 10-Q/earnings release. If revenue growth decelerates and receivables/inventory remain elevated, use any relief rally to re-establish a short with a stop above the pre-press-release range.
• If options liquidity is adequate, buy 1-3 month put spreads on ADMA instead of naked short stock to express the legal/quality-of-growth thesis with defined risk. Best setup is on a rebound toward the gap area, where implied vol should still be below event-driven realized volatility.
• Pair trade: short ADMA vs long GRFS or CSL over the next 3-6 months to isolate company-specific accounting/quality risk from underlying IVIG demand. The thesis breaks if ADMA shows no inventory unwind and continues to print repeatable growth without material margin or cash conversion deterioration.
• Set a hard watch item for any auditor, SEC, or restatement language; that is the catalyst that can extend this from a litigation headline into a structural de-rating. If no such follow-up appears by the next earnings cycle, reduce bearish exposure as the market may have over-discounted the complaint.